Key Documents

View All Documentation

P4498

Pravastatin sodium salt hydrate

Name: Pravastatin sodium salt hydrate
Brand: SIGMA

synthetic (organic), ≥98% (HPLC), HMG-CoA reductase inhibitor, powder

Synonym(s):

(βR, δR,1S,2S,6S,8S,8aR)-1,2,6,7,8,8a-Hexahydro-β, δ,6-trihydroxy-2-methyl-8[(2S)-2-methyl-1-oxobutoxyl]-1-naphthaleneheptanoic acid sodium hydrate, Eptastatin sodium salt hydrate

Select a Size

Change View

About This Item

Empirical Formula (Hill Notation):

C₂₃H₃₅O₇Na · xH₂O

CAS Number:

81131-70-6

Molecular Weight:

446.51 (anhydrous basis)

UNSPSC Code:

12352200

PubChem Substance ID:

329820206

NACRES:

NA.77

MDL number:

MFCD00887601

Assay:

≥98% (HPLC)

Form:

powder

Quality level:

100

Technical Service

Need help? Our team of experienced scientists is here for you.

Let Us Assist

Properties

Product Name

Pravastatin sodium salt hydrate, ≥98% (HPLC), powder

biological source

synthetic (organic)

Quality Level

100

assay

≥98% (HPLC)

form

powder

color

white

mp

171.2-173 °C

solubility

H₂O: >10 mg/mL

originator

Bristol-Myers Squibb

storage temp.

2-8°C

SMILES string

[Na+].[H][C@@](O)(CC[C@H]1[C@@H](C)C=CC2=C[C@@H](O)C[C@H](OC(=O)[C@@H](C)CC)[C@]12[H])C[C@@H](O)CC([O-])=O

InChI

1S/C23H36O7.Na/c1-4-13(2)23(29)30-20-11-17(25)9-15-6-5-14(3)19(22(15)20)8-7-16(24)10-18(26)12-21(27)28;/h5-6,9,13-14,16-20,22,24-26H,4,7-8,10-12H2,1-3H3,(H,27,28);/q;+1/p-1/t13-,14-,16+,17+,18+,19-,20-,22-;/m0./s1

InChI key

VWBQYTRBTXKKOG-IYNICTALSA-M

Gene Information

human ... HMGCR(3156)

Description

General description

Pravastatin sodium is an orally effective hypocholesterolaemic agent which is structurally similar to lovastatin and compactin.

Application

Pravastatin sodium salt hydrate has been used in the enzymatic method to measure mevalonic acid in serum.

Biochem/physiol Actions

Competitive, water-soluble 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor. Inhibits cholesterol synthesis in vivo (Ki ~1 nM).

Pravastatin sodium is a competitive, water-soluble 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor.

Features and Benefits

This compound was developed by Bristol-Myers Squibb. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Storage Class

11 - Combustible Solids

wgk

WGK 2

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

Eyeshields, Gloves, type N95 (US)

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Statins for treating stable angina: can statins improve the plaque morphology and angina?

Cheol Whan Lee et al.

Future cardiology, 9(2), 155-158 (2013-03-08)

Cost-effectiveness of statins for primary cardiovascular prevention in chronic kidney disease.

Kevin F Erickson et al.

Journal of the American College of Cardiology, 61(12), 1250-1258 (2013-03-19)

The authors sought to evaluate the cost-effectiveness of statins for primary prevention of myocardial infarction (MI) and stroke in patients with chronic kidney disease (CKD). Patients with CKD have an elevated risk of MI and stroke. Although HMG Co-A reductase

Disposition of pravastatin sodium, a tissue-selective HMG-CoA reductase inhibitor, in healthy subjects.

S M Singhvi et al.

British journal of clinical pharmacology, 29(2), 239-243 (1990-02-01)

Pravastatin sodium, a competitive inhibitor of HMG-CoA reductase, is a new orally effective hypocholesterolaemic agent. In a two-way crossover study, eight healthy male subjects each received an intravenous and an oral dose of [14C]-pravastatin sodium. The oral absorption of [14C]

View All Related Papers